Abemaciclib Does Not Improve OS in HR+/HER2- Breast Cancer
Adding abemaciclib to first-line nonsteroidal aromatase inhibitor treatment does not provide a significant improvement in OS for patients with HR+/HER2- advanced breast cancer, updated data suggest.